alginate, aluminium hydroxide, magnesium trisilicate, sodium bicarbonate drug combination: foaming antacid containing aluminum hydroxide gel, magnesium trisilicate, sodium bicarbonate & alginic acid [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 6336690 |
| MeSH ID | M0051253 |
| Synonym |
|---|
| alginic acid compound |
| foamcoat |
| gastrocote |
| alginic acid, mixt. with aluminum hydroxide, silicic acid (h4si3o8) magnesium salt (1:2) and sodium hydrogen carbonate |
| gaviscon |
| aac (combination) |
| foamicon |
| quigel |
| aluminum hydroxide and magnesium trisilicate |
| 66220-44-8 |
| alginate, aluminium hydroxide, magnesium trisilicate, sodium bicarbonate drug combination |
| Excerpt | Reference | Relevance |
|---|---|---|
| "Sideropenia is often encountered in medical practice; the iron preparation that presents the highest bioavailability is unquestionably iron sulphate." | ( [Bioavailability of orally administered iron. Effects of alginate/antacid administration]. Breda, E; Campo, S, 1992) | 0.28 |
| Excerpt | Relevance | Reference |
|---|---|---|
| "Gamma scintigraphy was used in twelve healthy volunteers to establish whether the time of dosing of Liquid Gaviscon relative to a meal influenced its therapeutic action." | ( Effect of time of dosing relative to a meal on the raft formation of an anti-reflux agent. Greaves, JL; Washington, N; Wilson, CG, 1990) | 0.28 |
| " The reduced dosage volume of the 'new' preparation (Gaviscon Advance) may be expected to improve patient compliance, and thereby increase treatment efficacy." | ( A comparison of the efficacy of the alginate preparation, Gaviscon Advance, with placebo in the treatment of gastro-oesophageal reflux disease. Chatfield, S, 1999) | 0.3 |
| "The aim of this study was to compare alginate products with the same amount of active ingredients but different dosage forms, in the suppression of reflux provoked by a standard meal in healthy human volunteers, using ambulatory oesophageal pH monitoring." | ( The suppression of gastro-oesophageal reflux by alginates. Berry, PJ; Dettmar, PW; Hampson, FC; Johnstone, LM; Lorch, U; Sykes, J; Taubel, J, 2007) | 0.34 |
| " There were also no significant differences between the two alginate dosage forms in the angular transformed percentage of time for which oesophageal pH fell below five and in the log-transformed number of occasions on which oesophageal pH fell below four and five." | ( The suppression of gastro-oesophageal reflux by alginates. Berry, PJ; Dettmar, PW; Hampson, FC; Johnstone, LM; Lorch, U; Sykes, J; Taubel, J, 2007) | 0.34 |
| " If patients had been started on a PPI prior to their JVC attendance, this was optimised to a twice-daily dosing regimen and continued." | ( Gaviscon® Advance alone versus co-prescription of Gaviscon® Advance and proton pump inhibitors in the treatment of laryngopharyngeal reflux. Fraser, HM; Raja, H; Wilkie, MD, 2018) | 0.48 |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 29 (26.85) | 18.7374 |
| 1990's | 21 (19.44) | 18.2507 |
| 2000's | 21 (19.44) | 29.6817 |
| 2010's | 34 (31.48) | 24.3611 |
| 2020's | 3 (2.78) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (9.45) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 50 (43.10%) | 5.53% |
| Reviews | 7 (6.03%) | 6.00% |
| Case Studies | 10 (8.62%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 49 (42.24%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The Impact of Adjuvant Liquid Alginate on Endoscopic Ablation Therapy of Complicated Barrett's Esophagus: A Pilot Study [NCT03193216] | Phase 2 | 24 participants (Actual) | Interventional | 2017-08-25 | Completed | ||
| A Multi-centre, Randomised, Open Label, Placebo-controlled, Two-period Crossover Study to Evaluate 4-hour Esophageal pH Change in GERD Patients After Administration of Compound Sodium Alginate Oral Suspension Sachets or Placebo Sachets [NCT02619747] | Phase 3 | 16 participants (Actual) | Interventional | 2014-04-30 | Terminated(stopped due to Problems with recruitment) | ||
| A Randomized, Open-label, 2-Treatment Crossover Study to Compare by Scintigraphy, the Antireflux Activity of the To-be-Registered Product (250 mg Sodium Alginate/187.5 mg Calcium Carbonate/106.5 mg Sodium Hydrogen Carbonate) Chewable Tablets Versus the Re [NCT03065816] | Phase 1 | 34 participants (Actual) | Interventional | 2017-02-09 | Completed | ||
| 48 Hoursesophagal pH-monitoring With and Without Gaviscon [NCT02783378] | 50 participants (Actual) | Interventional | 2016-02-24 | Completed | |||
| A Multi-centred, Randomised, Double-blind, Two Arms, Parallel Group, Placebo-controlled Study to Assess the Effect of Compound Sodium Alginate Oral Suspension Sachet in Patients With Reflux Disease [NCT02623062] | Phase 3 | 644 participants (Actual) | Interventional | 2013-12-31 | Completed | ||
| A Multi-centre, Randomised, Double-blind, Two Arm, Parallel Group, Placebo-controlled Study to Assess the Effect of Compound Sodium Alginate Double Action Chewable Tablets in Patients With Gastro-esophageal Reflux Disease [NCT01869491] | Phase 3 | 1,107 participants (Actual) | Interventional | 2013-06-30 | Completed | ||
| A Multi-centred, Randomised, Open Label, Placebo-controlled, Two-period Crossover Study to Evaluate 4-hour Esophageal pH Change in GERD Patients After Administration of Compound Sodium Alginate Double Action Tablets or Placebo Tablets [NCT01872897] | Phase 3 | 45 participants (Actual) | Interventional | 2013-06-30 | Completed | ||
| A Randomized, Open Label, 2-Treatment Crossover Study to Compare by pH Metry, the Antacid Activity of the To-be-registered Product (250 mg Sodium Alginate/187.5 mg Calcium Carbonate/106.5 mg Sodium Hydrogen Carbonate, Chewable Tablets) Versus the Register [NCT03069963] | Phase 1 | 24 participants (Actual) | Interventional | 2017-02-24 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||